Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on July 13, 2010, by Emergent BioSolutions Inc. (Delaware). The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing Inc., a wholly-owned subsidiary of the Registrant.
Key Financial Metrics and Contract Value
The filing discloses a new cost-plus-fixed-fee development contract with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. The contract is valued at up to approximately $107 million.
- Total Contract Value: Up to approximately $107 million.
- Base Period Value: Approximately $54.6 million for a two-year period (July 19, 2010 to July 18, 2012).
- Option Period Value: Approximately $52.3 million for three potential option years.
- Maximum Contract Duration: Up to July 18, 2015, contingent on option exercises.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the company's overall financial position.
Material Changes and Contract Scope
The primary material change is the execution of the agreement to develop and obtain regulatory approval for large-scale manufacturing of BioThrax (Anthrax Vaccine Adsorbed) at the Registrant's facility in Lansing, Michigan.
- Base Period Activities: Completion of characterization and immunogenicity studies, successful consistency lot validation, and a pre-IND meeting.
- Option Period Activities: Potential stability demonstrations, clinical studies, and biologics licensing application activities.
Outlook, Risks, and Management Commentary
Management highlights the strategic importance of the agreement for the development of BioThrax. The contract structure includes a base period with three optional years, meaning the full $107 million value is contingent upon BARDA exercising the options. The filing does not explicitly list new risks or contingencies beyond the standard nature of development contracts.
Key Facts for Investor Verification
- Verify the specific terms and conditions of the cost-plus-fixed-fee structure in the full agreement.
- Monitor the exercise of the three option years by BARDA to determine if the full $107 million value will be realized.
- Track progress on the base period milestones: characterization studies, immunogenicity studies, consistency lot validation, and the pre-IND meeting.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the strategic impact.